AI-generated summary
The authors studied whether light therapy at 850, 630 and 460 nm could relieve primary dysmenorrhea in an animal model and in prostaglandin-F2α-treated human cells. They report that all three wavelengths reduced pain and reduced PGF2α, with 630 nm showing the best effect. In cells, red light restored calcium, ROS, ATP and mitochondrial membrane potential toward normal levels. The authors suggest red light therapy may be a promising future clinical approach.
- Who or what was studied
- Animal model of primary dysmenorrhea and prostaglandin-F2α-induced human uterine smooth muscle (HUSM) cells
- Wavelengths
- 850, 630, 460 nm
- Limits stated in the abstract
- The abstract does not report sample sizes, control groups or clinical testing in patients, so the findings are preclinical and their clinical relevance is unclear.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm, 630 nm, 460 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Reactive oxygen species, Adenosine triphosphate, Inflammation, Irradiance. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.